Available online at www.ijpab.com

DOI: http://dx.doi.org/10.18782/2582-2845.9030

ISSN: 2582 – 2845

Ind. J. Pure App. Biosci. (2023) *11*(6), 1-9

Indian Journal of Pure & Applied Biosciences

Peer-Reviewed, Refereed, Open Access Journal

Review Article

Cancer Pharmacology Advances: Fundamentals, Combination, Imagery, Shipment and Therapeutic Applications

Muhammad Waseem Nazar[1], Qurat Ul Ain Asif[2*], Uzma Kousar[2], Muhammad Huzaifah Khalid[3], Ali Nawaz[4], Zaighum Ali[5], Muhammad Saqib[6], Muhammad Ahmad[7]

[1]Department of Clinical Sciences, University of Veterinary and Animal Sciences, Sub Campus Jhang

[2]Department of Pharmaceutical Sciences, The University of Faisalabad

[3]Department of Clinical Medicine and Surgery, The University of Agriculture, Faisalabad

[4]Department of Livestock Management, The University of Agriculture, Peshawar

[5]Faculty of Veterinary Sciences, Bahauddin Zikiriya University, Multan

[6]Insitute of Physiology and Pharmacology, The University of Agriculture, Faisalabad

[7]Faculty of Veterinary and Animal Sciences, The Islamia University, Bahawalpur

*Corresponding Author E-mail: qurratulainasifasif@gmail.com

Received: 13.07.2023 | Revised: 24.09.2023 | Accepted: 9.11.2023

ABSTRACT

Cancer continues to be a major health issue worldwide, necessitating creative solutions to medication production and therapy techniques. It delves into the concepts of cancer drug activity, mixtures of drugs, imaging of molecules, delivery of medications, the interaction between medications, clinical utility and use, and the place of cancer medications across the procedure for discovering and developing drugs. Cancer therapy assumptions serve as the cornerstone for treatment methods. This understanding contributes directly to the intelligent planning of focused medicines, which aim to deliberately interrupt these channels while minimizing outside-target consequences and adverse reactions. Genome and transcriptomic studies have supplied a lot of understanding to aid in inventing personalized treatment techniques in cancer treatment. Cancer pharmaco has been transformed by molecular imaging tools that provide immediate visualization of medication action in the tumour ecosystem. Investigators can monitor medication transportation, pharmaceutical kinetics, and therapeutic using PET and MRI, as well as other approaches, supporting personalized regimens for therapy. Cancer medication means of distribution have emerged in order to increase drug absorption, decrease poisoning, or enhance directed drug administration. Creative ideas for drug delivery techniques that have shown interest in clinical studies include micron-sized particles of liposomes and antibody-drug conjugates. In cancer survivors, extensive toxicological research and computer modelling are critical in discovering likely interactions and guiding choosing therapy and administration. Cancer pharmacology's clinical significance and applications span from test to bed.

Keywords: *Cancer, Drug delivery techniques, Genome, PET, MRI*

Cite this article: Nazar, M.W., Asif, Q.U.A., Kousar, U., Khalid, M.H., Nawaz, A., Ali, Z., Saqib, M., Ahmad, M. (2023). Cancer Pharmacology Advances: Fundamentals, Combination, Imagery, Shipment and Therapeutic Applications, *Ind. J. Pure App. Biosci. 11*(6), 1-9. doi: http://dx.doi.org/10.18782/2582-2845.9030

INTRODUCTION

Many research conducted in the last two decades has not supported the notion that significant gains in treatment for cancer may be achieved merely by enhancing our understanding of the general pharmaco of deadly medicines. Measurements on medicine and constituent levels in the blood have enabled the effective discovery of many kinds of novel medicines and have been beneficial in dictating schedules of administration and the creation of innovative prodrugs. However, the intention of employing clinical medication to individualize therapies to optimize the medical care of each cancer in every client has yet to be met. Clinical pharmacology research continues to yield increasingly specific information on traditional cytotoxic medicines. Nevertheless, exclusive to cocaine (Jodrell, Egorin et al. 1992, Van Warmerdam, Rodenhuis et al. 1996) and maybe even for this medication (Evans, Relling et al. 1998) and etoposide (Braybrooke, Levitt et al. 2003) there is an argument for individualized dosing purely on persistent medication expertise. In this evaluation, I will concentrate on technical and psychological advances that have expanded the comprehension of 'classical cytotoxic' medications over basic measures for the entire substance or byproducts in circulation. New technology, incorporating genes and additional physiological drivers of pharmacy, and fresh quantitative and data-based analytic methodologies are among the breakthroughs. For the sake of the present debate, classical cytotoxic chemotherapy has been defined as a procedure that uses chemicals that have an unspecific impact on dividing cells or create cancer.

A number of these medications were tested in humans before any full understanding of their method of effect was known. To this regard, conventional brokers differ from newer created specific methods, in which medications have been intentionally created to interact with a designated carcinogenic destination (Cobleigh, Vogel et al. 1999, Druker, Talpaz et al. 2001). Despite the chemical composition of 'traditional' cytotoxic medications, which might hold a certain importance for more particular employees, these are unrelated to any distinct biological features.

Cancer pharmaceuticals provides a single source of real-world expertise that is useful for an extensive number of purposes concerning therapies for cancer, from daily clinical decisions about treatment to help developing clinical trials in the creation of medications, to finding and assessing of molecules that might be candidates for advancement to clinic therapy. The transition beyond continuous to oral medication administration in individuals with cancer. One of particularly visible indicators of the relevance of cancer pharmacological is the tremendous and continual development of the range of medications offered for managing cancer. Over two hundred products have been licenced for commercialization in chemotherapy, including 51 that were cleared by the US Food and Drug Administration (FDA) between 2011 and 2015. Additionally, 15 were granted in 2015 (Table).The National Cancer Institute (NCI) began the main funding provider of novel cancer treatments when ASCO was created, and the NCI maintains to run a large cancer medication discovery programme. NCI also works together with commerce and other organizations. The chemical industry has significantly boosted its investment in cancer medication over the last 25 years. Numerous charitable groups are also involved in cancer treatment research, although the business sector is the biggest beneficiary to the endeavour to deliver novel cancer medicines to patients. Aside from the tremendous growth in the quantity of cancer medications accessible, more factors are profoundly altering the way oncologists and drug researchers discover, produce, and recommend therapies for individuals with cancer. (Yao, Barlow, and others). There also has a countertrend: requesting approval of

drugs based on a medicine's targeting as opposed to its biological region.

Furthermore, although reliable therapy for first-line management of many malignancies is more readily accessible, provisional authorization are additionally categorized by the level of past surgery. Imatinib's authorization in 2001 signalled three of the most drastic advances in treatments for cancer, heralding whole novel models that developed ubiquitous over over the following 15 decades. Molecular focusing on, diagnostic procedures related with drug selection, and immunotherapy.

Even though the following section, concentrates on small, synthetic compounds, one of the most interesting discoveries in cancer pharmacological is the successful move of autoantibodies through the research phase towards complete absorption with tiny substances in therapy for patients. Despite their differences size-wise and fabrication processes, the research approaches for these new pharmacological classes share similar objectives involving tiny molecules, such as the regulation on particular biological targets and coupling to an examination associated with that schedule. The medication combines all of these aspects, particularly its recent FDA clearance of ado-trastuzumab emtansine as an antibody-drug combination. The quick accessibility of new treatments and fresh insights for how to apply the drugs properly, specifically the capacity to prevent drug-drug and drug-food combinations, is a really helpful condition for individuals with cancer. Which will physicians maintain up with the flood of data on all these distinct difficulties? Anything a cancer doctor wants understand cannot be crammed into a compact booklet that slips in the wallet of the doctor's white coat. Computerized publications and centralized cloud-based databases aid in the provision of complicated data. The objective of this review is on the tenets related to cancer pharmacology and their ability to assist categorize and organizing data into valuable information (Collins, 2020).

Topoisomerase-targeting medicines are a diverse class of chemicals with diverse therapeutic effects that are distinguished by their capacity to affect their target molecules topoisomerases or their prokaryotic equivalents (Gellert 1981, Liu 1989). Topoisomerases are a type of atomic protease that is responsible for resolving topological issues that arise during ordinary physiological nucleotide translation. Since the discovery of an early enzyme capable of catalyzing topological processes, the protein co in E. coli (Wang 1969), enzymes with topoisomerase capability has been discovered in nearly every creature examined. Their widespread adoption, as well as considerable similarity in their core patterns, are related to the "mechanical" issues brought about by the molecule’s complexities to any helix-processing process. Many reviews have been written on the reactions catalyzed by topoisomerases and their roles in basic functions such as reproduction, transcription, and rearrangement (Froelich-Ammon and Osheroff 1995, Gatto and Liu 1998), thus they will not be discussed here. All topoisomerases towards their protein substrate share the nicking-closing operation. (1980, Been and Champoux) Topoisomerases are categorized into two types on the basis of their method of action, type I and type II enzymes; x In every aspect known topoisomerases have lately been grouped into three classes based on nucleotide homologies and biological features. 1998 (Gatto and Liu) Eukaryotic topoisomerase I and the vaccination virustopo I are members of a family whose agents of attack are discussed in this chapter.

Nevertheless, considering the variances in the subdomain organization of the two enzymatic agents a recent research proposes that they belong to different subfamilies, a notion corroborated through the incomplete structural description of both substrates. (Sharma, Hanai, and colleagues 1994; Lue, Sharma, and colleagues 1995) Patients with mutants p53-bearing tumours will not benefit from gSK3 medications. Drugs were looked because of that were going to be efficient in cultures with a transgenic retinoblastoma gene (pRb) in a p53-null

context. They achieved this by creating a driven genes called e2f1. The active hypophosphorylated retinoblastoma protein, Rb1, particularly binds with and inhibits the e2f1 interaction. Rb1 is phosphorylated during the late g1 is period in a cells life cycle, as the organism begins for entering the phase known as S. This method was utilized for evaluating molecules that might cause apoptotic when e2f1 was activated, and it was shown that histone deacetylase inhibitors (HDAcI) triggered planned cell death in cells disrupted in the e2f1/Rb/p16 pathway (Zhao, Tan et al. 2005). Molecular changes to DNA proteins that bind the histones, generally by methylation and acetylation, impact epigenetic regulation of the transcription of genes. A class of deacetylases that can be scientifically controlled by HDACIs is a significant mechanism controlling histone acetylation. It was discovered that inhibiting HDAc increased e2f1 connecting and expression of the Bim activator. Bim was later identified as the main contributor in the production of apoptosis following simultaneous HDAc restriction and e2f1 expression. These research studies introduce the notion of "constrained" perturbation testing.

Principles of Cancer Drug Action:

Genomics is a critical component in cancer studies. Congenital susceptibility and combinations of heritability with nonhereditary determinants are examples of genomic effects on cancer. The primary one focus of Pharmaceutical Genomics in cancer medicine has been on DNA targets that may be important to treatments. This focus encompasses translocation-coded proteins, variations in gene transcription across tumours and host organs, and genome polymorphisms. The capacity to identify the most appealing molecule targets and measure targeting involvement through chemotherapy are critical components of personalized medicine. As previously stated and elsewhere, the knowledge of tumour physiological and molecular anatomy has revealed many prospective candidates for cancer chemotherapy. Despite the fact that the amount has increased. Amongst the very initial productive uses of biological retargeting was determining the type of steroids for people whose tumours express the oestrogen protein. The present day age of focusing begins with the marketing of trastuzumab (1998) in just those suffering from Her2-positive tumours and imatinib (2001) specifically in adults with Philadelphia chromosomal high prolongedmyelogenous leukaemia (CML). These early achievements stimulated focus on further goals. The technique has numerous family members, including ALK and BRAF.

The intent became more important in 2017 with the acceptance of pembrolizumab for the therapy of tumours with error repair or persistent unsteadiness, regardless of the tumour's location of origin. Aside from the obvious appeal of tailoring medications to the molecular makeup of the tumour. The researchers wanted to see if participants' hereditary DNA changed the toxicological makeup of cyclophosphamide. The team of investigators discovered a subset of women with variable GSTP1 variants who had been less susceptible to severe hematopoietic damage in cyclophosphamide programmes. Further studies by big collaborative associations in the UK for chemotherapy in the treatment of breast cancer (Abraham, Guo et al. 2014) and in the US for docetaxel in prostate carcinoma (Hertz, Owzar et al. 2016) discovered additional linkages among hereditary DNA and neurological disorders. Though these investigations were hypothesis-generating, the illustrations show how the therapeutic efficacy of a medicine might be enhanced through examining host tissues. Later throughout this chapter, when discussing how drugs are delivered, the medications will be discussed.



Fig: Antitumor agents

Combinations of Drugs

It is uncommon for a medicine to be employed as an individual, as explained in the numerous chapters communicating to distinct cancers in the third chapter of this book. Combine formation could be a lengthy topic in and of themselves. Box 25.1 is a list of items to look at while putting together an amalgamation. The medications in the oncology regimen are designed for pharmacodynamic interaction. Initially, combining cancer medicines with no overlapping harms was a key focus. More in-depth understanding of cancer medication networks allows for the development as well as assessment of combined tactics which target concurrent and/or progressive pathways. The majority of pairings rely on a proven basis in science or the integration of a new medication to an extant schedule. The methodical review of all cancer medications when utilized with other treatments or in cooperation with licenced treatments within cancer therapy, or the clinical trial for each prospective agent vs all current cancer medications, is one approach for broadening the realm of creating hypotheses. Kumar, Chen, and colleagues (2010) Whereas such testing method began as an empirical sport, the effective pairings raise questions about the root causes of activation. The primary goal on already-approved medications enable a possible quick path to clinical trials (Holbeck, Camalier, and colleagues (2017).

Molecular Imaging of Cancer Drug Action

With the increasing affordability of fluorine-18 fluorodeoxyglucose (18F-FDG), there was universal agreement in the second half of the 1990s that PET was going to become a means for evaluation of function that complemented morphological scans. (Niederhuber, 1998) Since that point, FDG has become a highly productive generalist investigation in many tumour forms, offering additional details to assist with differentiating dangerous from harmless tumours and evaluating reactions to chemotherapy. FDG has been a recognized radiographic tool. The achievement has sparked fascination with the creation of other PET scanning devices that are now in the exploratory stage of peer review, such as fluorine-18 fluorothymidine (18F-fluorothymidine; FLT).(Liu et al). FLT capability was shown in someone with cancer of the uterus. Liu, Jeraj, and colleagues (2011) The FLT image indicates significant absorption by the tumour at starting point, indicating continuous development. sunscreen medication lowered FLT accumulation in the tumour, which was seen as lower proliferative. During medication removal, the resultant

picture displayed a f lare—that is, brilliance that recovered above the initial value. Anatomic screening with CT (computed tomography) quickly detected the tumour and may monitor tumour development over a period of days or weeks, while FLT allowed researchers to watch biological processes in actual time.

Cancer Drug Delivery:

Exposure at the Systemic Level The most essential practical challenge in practical cancer pharmacy is the choice of a sufficient dosage after the proper therapy has been successfully identified. The previously established average dose identified in general research is the basis for evaluation, but what situations could cause the dosage to be too large or too little for specific individuals? Many cancer therapies do not have guidelines based on evidence. In some circumstances, dose adjustment guidance is offered based on previous courses of therapy or age. Cancer medications have begun to be licenced with details concerning dosage adjustments depending on the results of renal examination, diet, and the use with additional drugs. All of these variables can cause variation in systematic exposure. As a result, the administered medication reaches both the tumour and normal cells. As mentioned in Box 25.3, elimination is a count of all processes for removing medication from the bloodstream, often known as total body elimination. The following sections go over several distinct uses of clearing for dose modification. The following concept described in Box 25.2 is accessibility, which measures how much medicine penetrates the bloodstream. Absorption has become more crucial because of the move towards medications taken by mouth. This notion is expanded under the part focusing on Oral Cancer Drugs. The half- life was traditionally the most researched criteria for cancer medication administration. Nevertheless, its primary duty is to assist in the exploration of administrative frequencies during the building period. Oncologists do not use a medicine until it has been licenced for clinical use.

Drug-Drug Interactions

There are numerous types of drug-drug interactions. Anticancer treatments in chemotherapeutic regimens, whose effects are normally meant to work at the cellular level of drug action processes, are just the leading edge of the ice in terms of interaction between drugs. People with cancer receive treatment with medications for a variety of other ailments, include heart, digestive , and lung disorders, transmission, depression, even pain management. All of such polypharmacy combinations have the potential to influence cumulative exposure and, consequently cancer drug delivery to tumour and normal tissue. As a result of these communications, conventional pharmacological beginning dosage can have be drastically reduced or addressed. The majority of drug-drug interactions are classified as unsafe due to increased exposure to the system. However, while this sort of interaction is "invisible" because of increased toxic relationships, lower medication administration might result in the most detrimental consequence of all: decreased efficacy. Medication-drug physiological reactions occur with systemic methods of administering drugs, but mouth routes are significantly more prevalent. Considering catabolism is the key regulator of removal for the vast majority of medicines, it is the primary control of deviations in concentrations in the blood. According to the approach in Box 25.3, drug absorption suppression via an interaction with a drug results in reduced clearance and, consequently greater systemic exposure. To avoid increasing toxicity, a dose reduction may be required. In contrast, medications like doxycycline can promote the production of specific metabolizing proteins, which reduces system quantities of pharmaceuticals cleared by those digestive enzymes because their digestion is faster. A decreased chance raises the likelihood of insufficient cancer medication delivery to the tumour. If higher-dosage safety data is offered, a possible strategy is to raise the amount being taken. Otherwise, surfing switching to a new therapy regimen may be essential. Table 25.2, in the part that focuses on oral tumour medicines, gives some instances of enzyme networks that metabolize cancer medicines.

CLINICAL RELEVANCE AND APPLICATIONS

Malignant pharmacology's medical mission is to advise or guide physicians in treatment selection. Cancer pharmaceuticals, which

encompasses creation, model-based verification, toxicity, PK, and PD examinations, is also a crucial element in getting medicines from laboratory testing to clinical trials. The hunt for indicators and the measurement of therapy benefits are important steps in front in the comprehension of cancer-related medication activities. In the future, probably a particularly important topic of cancer pharmacotherapy is the search for and deployment of prospective biomarkers with predictive value for treatment decision and maintenance. The present research is being conducted to create ways for selecting therapy for individuals that utilize the molecular makeup of their tumours, which includes DNA (particularly mutations), RNA (expression collections and immediate polymerase), and other factors.

This is too soon to draw judgements about the long-term roles of such investigations. It is becoming progressively recognized that every single one of those conclusion points has unique sample processing needs that are critical to the meaning of the outcome. Additionally, interlaboratory assessment has risen to the forefront of the checklist of prerequisites for making meaningful success with this type of technology. Carcinoma treatment delivery aids in deciding of appropriate quantities, timings, and administering channels. The easiest and most appealing method for customizing dosage to clients would be offering advice before the initial injection to avoid unintended consequences and maximize curative delivery. Previous chapters on the compromised functioning of organs and interaction between drugs explored some little steps towards this objective. When therapy is continuing, changes frequently become necessary. The most pressing necessity is always adjusting dosages based on unforeseen consequences. If there is serious or excruciating toxicity, its anticancer properties will be deemed ineffective. A certain amount of change caused by the absence of efficacy against tumours has its appeal, especially if the harmful effect is lower than predicted, indicating sufficient exposure. Nevertheless understanding of the restricted therapeutic window for cancer medications, as well as numerous other precautionary clinical criteria or risk factors, are usually against raising the dosage additional compared to the accepted unless sufficient security confirmation for greater dosages is known. Furthermore, there is always the sensation that if the currently employed treatment fails to benefit the patient, transitioning to an alternative therapy is critical before the tumour spreads.

CANCER PHARMACOLOGY ACROSS THE DRUG DISCOVERY AND DEVELOPMENT PROCESS:

The utilization of cancer pharmaco principles has been incorporated in the progression from earliest drug identification to embryonic growth and ultimately to the prior authorization phase of clinical testing. It is critical to keep tabs on the degree of distribution of drugs, as measured by systemic quantity, during the making phases of cancer therapy. Concentrations in plasma can be evaluated while conducting activity investigations in murine theories, safety research in diverse human beings, or early clinical trials. Changes across the models of animals may indicate significant interspecies variants in elements connected with both PK (e.g., metabolism) or PD (e.g., built-in cell lineage sensitivity). Similarly, when comparing findings of behaviour in growing cells to quantities that may have been securely generated in live animals, it is wise to consider causes. Scepticism is especially warranted when "exciting" behaviour is demonstrated via in vitro experimentation at dosages far greater than those feasible in vivo. Oncologypharmacology's results can be detected in the pathways that lead medications into clinical usage and in the adaptation that occurs for clients to reconcile medicinal and harmful consequences. Addressing the links underlying malignancy delivery of drugs and statistical elements of chemotherapy action and toxicology is critical for future success. The disease drug administration may only offer beneficial concentrations while avoiding hazardous amounts if relevant distinctions between tumour and host tissues are discovered and accurate diagnostics can be accessed at the laboratory-clinic contact.

Acknowledgement:

This creative scientific literature, an acknowledgement is an expression of gratitude for assistance in creating an original work

Funding:

No Funding for this paper

Conflict of interest:

There is no Conflict of interest between Authors

Authors Contribution:

All Authors are contributed equally, and all authors' responses are observed

REFERENCES

Abraham, J. E., et al. (2014). "Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel." *Clinical cancer research 20*(9): 2466-2475.

Been, M. D. and J. J. Champoux (1980). Breakage of single-stranded DNA by rat liver nicking-closing enzyme with the formation of a DNA-enzyme complex. *Nucleic Acids Research 8*(24): 6129-6142.

Braybrooke, J. P., et al. (2003). "Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIα expression." *Clinical cancer research 9*(13): 4682-4688.

Cobleigh, M. A., et al. (1999). "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease." *Journal of clinical oncology 17*(9), 2639-2639.

Collins, J. M. (2020). Cancer pharmacology. Abeloff's Clinical Oncology, *Elsevier*: 411-419. e44

Druker, B. J., et al. (2001). "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *New England Journal of Medicine, 344*(14), 1031-1037.

Evans, W. E., et al. (1998). Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. *New England Journal of Medicine 338*(8), 499-505.

Froelich-Ammon, S. J. and N. Osheroff (1995). Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism. *Journal of Biological Chemistry, 270*(37), 21429-21432.

Gatto, B. and L. F. Liu (1998). Topoisomerase I-targeting drugs: new developments in cancer pharmacology. Advances in DNA Sequence-Specific Agents, *Elsevier*. *3*, 39-66.

Gellert, M. (1981). DNA topoisomerases. *Annual review of biochemistry 50*(1), 879-910.

Hertz, D. L., et al. (2016). Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. *Clinical cancer research 22*(19), 4890-4900.

Holbeck, S. L., et al. (2017). The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. *Cancer research 77*(13), 3564-3576.

Jodrell, D. I., et al. (1992). "Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer." *Journal of Clinical Oncology 10*(4), 520-528.

Kummar, S., et al. (2010). "Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. *Nature reviews Drug discovery 9*(11), 843-856.

Liu, G., et al. (2011). "Pharmacodynamic study using FLT PET/CT in patients

with renal cell cancer and other solid malignancies treated with sunitinib malate. *Clinical cancer Research 17*(24), 7634-7644.

Liu, L. F. (1989). "DNA topoisomerase poisons as antitumor drugs. *Annual review of Biochemistry 58*(1): 351-375.

Lue, N., et al. (1995). "A 26 kDa yeast DNA topoisomerase I fragment: crystallographic structure and mechanistic implications. *Structure 3*(12), 1315-1322.

Niederhuber, J. E. (1998). Future of positron-emission tomography in oncology. *Annals of surgery 227*(3), 324.

Sharma, A., et al. (1994). Crystal structure of the amino-terminal fragment of vaccinia virus DNA topoisomerase I at 1.6 Å resolution. *Structure 2*(8), 767-777.

Van Warmerdam, L., et al. (1996). Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. *British journal of cancer 73*(8), 979-984.

Wang, J. C. (1969). Degree of superhelicity of covalently closed cyclic DNA's from Escherichia coli. *Journal of Molecular Biology 43*(2), 263-272.

Yao, S., et al. (2010). Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. *Clinical cancer research 16*(24), 6169-6176.

Zhao, Y., et al. (2005). Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. *Proceedings of the National Academy of Sciences 102*(44), 16090-16095.